The present invention provides crystalline Form R of 2-[3-cyano-4-(2- methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid, process for its preparation, pharmaceutical composition comprising it and its use for the chronic management of hyperuricemia in patients with gout.